الفهرس Only 14 pages are availabe for public view
 |  | from | 180 |  |  |
| | | from | 180 | | |
Abstract
Background and aim: Cardiovascular disease rose to become leading causes of death. High mortality of cardiotoxicity originates in part from severe complications like cardiac contractile dysfunction and/or sudden cardiac death caused by ventricular arrhythmias pravastatin is antihyperlipidemic agent used to lower LDL cholesterol. Objectives: This experimental study was designed to investigate the potential role of pravastatin, the well known antihyperlipidemic drug, on cardiotoxicity observed in hearts of rats injected with cisplatin. Pravastatin was used in two specified doses and regimen of treatment, Results: normal rats that received pravastatin showed insignificant changes of all measured parameters except for p duration, QRS interval which showed a significant decrease in control group. Cardiotoxic untreated group showed hypotension, tachycardia, ECG changes, elevation of cardiac enzymes, IL-6, MPO. Treatment with pravastatin either oral or i.p decreased the elevated levels of these parameters, improved the increased levels of MPO. The marked histopathological changes and endothelial dysfunction induced by cisplatin were ameliorated in rats treated with pravastatin either oral or ip injection. Conclusion: The obtained data of the present study showed that pravastatin improved the cisplatin induced cardiotoxicity pravastatin could provide protective effects against cardiovascular complications in cancer chemotherapy (cisplatin) via pleiotropic, anti-inflammatory and its antioxidant role.